Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Aryldiazonium Salts to Azo Dyes: Diazo Coupling01:11

Aryldiazonium Salts to Azo Dyes: Diazo Coupling

3.1K
The reaction of weakly electrophilic aryldiazonium (also called arenediazonium) salts with highly activated aromatic compounds leads to the formation of products with an —N=N— link, called an azo linkage. This reaction, presented in Figure 1, is known as diazo coupling and occurs without the loss of the nitrogen atoms of the aryldiazonium salt. Highly activated aromatic compounds such as phenols or arylamines favor the diazo coupling reaction. The coupling generally occurs at the...
3.1K
Issues And Trends In Healthcare Delivery System01:29

Issues And Trends In Healthcare Delivery System

5.7K
The issues and trends in healthcare delivery are constantly changing. The COVID-19 pandemic is one recent issue that wreaked havoc on healthcare systems, causing a shortage of healthcare workers, high demand for medicines and supplies, and increased medical expenditure due to a lack of insurance. Other issues include rising healthcare costs and care fragmentation.
Cost Containment
Payment for healthcare services has historically promoted adoption of costly and often unnecessary or inefficient...
5.7K
Amines: Introduction01:07

Amines: Introduction

4.6K
Amines are organic derivatives of ammonia. They are formed by replacing one or more ammonia protons with alkyl or aryl groups. Depending upon the number of organyl groups bonded to nitrogen, amines are classified as primary, secondary, or tertiary. Primary amines have one organyl group attached to the nitrogen atom, while secondary and tertiary amines have two and three organyl groups attached to the nitrogen atom, respectively.
4.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Genomic landscape of acute myeloid leukemia in adolescents and young adults.

Leukemia·2026
Same author

<i>CEBP</i> and <i>ZEB2</i> alterations define three distinct subtypes of B-cell acute lymphoblastic leukemia.

HemaSphere·2026
Same author

An EHA strategic roadmap for improved care in Europe for AYA patients with malignant and chronic non-malignant hematological diseases.

HemaSphere·2026
Same author

Persistent <i>BCR::ABL1</i>-positive preleukemic stem cells drive late clonal evolution in Philadelphia chromosome-positive ALL.

HemaSphere·2026
Same author

A Europe-wide provider perspective of healthcare services for adolescent and young adult patients with haematological conditions: a survey from the Adolescent and Young Adult Taskforce of the European Hematology Association.

EClinicalMedicine·2026
Same author

Blinatumomab Consolidation for High-Risk Ph-negative B-cell Acute Lymphoblastic Leukemia: the GRAALL-2014/B-QUEST Study.

Blood·2026
Same journal

Nze C, Flowers CR. Barriers to accessing cellular therapy for patients receiving care in community practices. Hematology Am Soc Hematol Educ Program. 2023;2023(1):382-385.

Hematology. American Society of Hematology. Education Program·2025
Same journal

CAR T-cell therapy and bispecific antibodies in the management of multiple myeloma.

Hematology. American Society of Hematology. Education Program·2025
Same journal

Emerging immunotherapy advances for non-Hodgkin lymphomas: engaging T cells in the fight.

Hematology. American Society of Hematology. Education Program·2025
Same journal

Anticoagulants in hematologic malignancies: what is the data?

Hematology. American Society of Hematology. Education Program·2025
Same journal

Diagnosis and management of cold agglutinin disease.

Hematology. American Society of Hematology. Education Program·2025
Same journal

What to know about rare B-cell malignancies in 2025.

Hematology. American Society of Hematology. Education Program·2025
See all related articles

Related Experiment Video

Updated: Aug 18, 2025

All-optical Mechanobiology Interrogation of Yes-associated Protein in Human Cancer and Normal Cells using a Multi-functional System
09:55

All-optical Mechanobiology Interrogation of Yes-associated Protein in Human Cancer and Normal Cells using a Multi-functional System

Published on: December 20, 2021

3.0K

New developments in ALL in AYA.

Nicolas Boissel1

  • 1Adolescent and Young Adult Hematology Unit, Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris, Institut de Recherche Saint-Louis, Université Paris Cité, Paris, France.

Hematology. American Society of Hematology. Education Program
|December 9, 2022
PubMed
Summary
This summary is machine-generated.

Outcomes for adolescents and young adults with acute lymphoblastic leukemia (ALL) are improving with targeted therapies. Advances in ALL biology and risk stratification offer new hope for better treatment strategies and reduced toxicity.

More Related Videos

An In Vitro Preparation for Eliciting and Recording Feeding Motor Programs with Physiological Movements in Aplysia californica
11:49

An In Vitro Preparation for Eliciting and Recording Feeding Motor Programs with Physiological Movements in Aplysia californica

Published on: December 5, 2012

11.6K
Development of New Therapeutic Applications Using Microfluidics
08:56

Development of New Therapeutic Applications Using Microfluidics

Published on: October 1, 2007

5.5K

Related Experiment Videos

Last Updated: Aug 18, 2025

All-optical Mechanobiology Interrogation of Yes-associated Protein in Human Cancer and Normal Cells using a Multi-functional System
09:55

All-optical Mechanobiology Interrogation of Yes-associated Protein in Human Cancer and Normal Cells using a Multi-functional System

Published on: December 20, 2021

3.0K
An In Vitro Preparation for Eliciting and Recording Feeding Motor Programs with Physiological Movements in Aplysia californica
11:49

An In Vitro Preparation for Eliciting and Recording Feeding Motor Programs with Physiological Movements in Aplysia californica

Published on: December 5, 2012

11.6K
Development of New Therapeutic Applications Using Microfluidics
08:56

Development of New Therapeutic Applications Using Microfluidics

Published on: October 1, 2007

5.5K

Area of Science:

  • Hematology
  • Oncology
  • Pediatric Oncology

Background:

  • Outcomes for adolescents and young adults (AYA) with acute lymphoblastic leukemia (ALL) have improved due to pediatric-inspired protocols.
  • Treatment resistance and toxicity increase with age, necessitating novel therapeutic approaches.
  • Advances in ALL biology, risk stratification, and targeted therapies are crucial for further progress.

Purpose of the Study:

  • To review recent advancements in the treatment of ALL in adolescents and young adults.
  • To highlight the importance of understanding ALL biology for personalized treatment strategies.
  • To discuss the role of targeted therapies, immunotherapy, and minimal residual disease monitoring in improving outcomes.

Main Methods:

  • Review of current literature on ALL treatment in AYA.
  • Analysis of recent biological and genetic discoveries in ALL.
  • Evaluation of the impact of novel therapeutic strategies, including targeted small molecules and immunotherapy.
  • Assessment of the role of minimal residual disease (MRD) monitoring and comprehensive care programs.

Main Results:

  • The proportion of B-cell precursor ALL with "B-other" genetic drivers in AYA has significantly decreased.
  • Philadelphia-like ALL is a common high-risk subtype in AYA, presenting numerous actionable targets.
  • Early MRD monitoring is essential for risk stratification and guiding treatment decisions, including allogeneic stem cell transplantation.
  • Frontline immunotherapies are being employed to eradicate MRD and improve outcomes for high-risk patients.

Conclusions:

  • Further improvements in AYA ALL treatment rely on integrating advanced biological insights, precise risk stratification, and novel targeted therapies.
  • Timely identification of actionable targets, particularly in Philadelphia-like ALL, remains a challenge.
  • Immunotherapies and MRD monitoring are pivotal in enhancing treatment efficacy and reducing toxicity.
  • Comprehensive care programs are vital for supporting AYA patients throughout their cancer journey.